 | |
- close
- close
|
TheStreet.com
Nov 24
Comment
Will Cel-Sci's flu drug last longer than its other fly-by-night projects?
TheStreet.com
Nov 24
Comment
Hedge funds, Wall Street, SEC and FDA out to hurt maker of flu drug, newsletter writer claims.
Market Intelligence Center
Nov 20
Comment
BioCryst Pharmaceuticals (BCRX) leads the list of top losers so far today and is now at $9.72, down $0.68 (-6.54%) on volume of 4,947,233 shares traded. Last night BCRX priced an offering of common stock at $9.75. Over the last 52 weeks the stock...
StreetInsider.com
Nov 20
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/BioCryst+Pharma+%28BCRX%29+Priced+5M+Common+Offering+at+%249.75Share/5128967.html for the full story.
StreetInsider.com
Nov 17
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/BioCryst+Pharma+%28BCRX%29+Files+5M+Common+Stock+Shelf/5116598.html for the full story.
Shocked Investor
Nov 9
Comment
We track the companies that make H1N1-related products on this site.
The top performer year-to-date is BCRX (Biocryst), with a staggering return of 723%, followed by SVA (Sinovac), +492%. At least here in Canada, the few H1N1 deaths have been...
New York Times
Nov 6
Comment
Peramivir might also be a life saver for its developer, BioCryst Pharmaceuticals, an unprofitable biotechnology company in Birmingham, Ala.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
BCRX AT A GLANCE
References
| ||||||
|
|
